GBR 830, an anti-OX40, improves skin gene-signatures and clinical scores in atopic dermatitis.

Emma Guttman-Yassky,Ana B Pavel,Lisa Zhou,Yeriel D Estrada,Ning Zhang,Hui Xu,Xiangyu Peng,Huei-Chi Wen,Panayiota Govas,Girish Gudi,Vinu Ca,Hui Fang,Yacine Salhi,Jonathan Back, Venkateshwar Reddy,Robert Bissonnette,Catherine Maari, Fred Grossman,Gerhard Wolff

Journal of Allergy and Clinical Immunology（2019）

引用 126|浏览24

暂无评分

摘要

Two doses of GBR 830, 4-weeks apart, were well-tolerated and induced significant, progressive tissue and clinical changes until Day 71 (42 days after last dose), highlighting the potential of OX40-targeting in AD.

查看译文

关键词

Atopic dermatitis,inflammation,hyperplasia,OX40,costimulation,trial,TH1,TH2,TH17/TH22,biomarkers

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要